Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 Next >
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Third Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Third Quarter 2022 Financial Results on October 27
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Appoints Jonathan Biller as Chief Legal Officer
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Second Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances VX-548 in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Second Quarter 2022 Financial Results on August 4
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers CRSP VRTX
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Suketu Upadhyay Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports First Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce First Quarter 2022 Financial Results on May 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.